TakedaPresentsNewDataShowingMezagitamab(TAK-079)SustainedEffectonKidneyFunction18MonthsAfterTreatmentinPrimaryIgANephropathy
===2025/11/10 15:13:58===
h.gov/health-information/kidney-disease/iga-nephropathy#what. Accessed September 2025.
Contacts
Media:
Japanese Media
Yuko Yoneyama
yuko.yoneyama@takeda.com
U.S. and International Media
Takeda Media Relations
media_relations@takeda.com
=*=*=*=*=*=
当前为第15/15页
上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页